💊 Rapamycin mTOR Inhibition Longevity Simulator

mTOR — The Cell's Central Nutrient-Sensing Hub

Placeholder: mTOR integrates nutrient, energy, and growth-factor cues into one growth decision.

• mTORC1: Complex (Placeholder: primary longevity-relevant complex)
• 4: Key inputs (Placeholder: amino acids, energy, growth factors, oxygen)
• Yeast→Human: Conservation (Placeholder: pathway conserved across eukaryotes)
• 1990s: Discovery era (Placeholder: TOR first identified in yeast)

What mTORC1 senses

Placeholder: amino acid and energy sensing inputs to mTORC1.

Growth vs. maintenance trade-off

Placeholder: high mTOR activity favors growth over cellular upkeep.

Why nutrient sensing links to aging

Placeholder: chronic nutrient-sensing overactivation is tied to aging.

Placeholder key insight: mTOR sits at the crossroads of growth and longevity signaling.

Rapamycin Binding and Allosteric mTOR Inhibition

Placeholder: rapamycin forms a ternary complex with FKBP12 to inhibit mTORC1.

• FKBP12: Binding partner (Placeholder: immunophilin co-receptor)
• Easter Island: Origin (Placeholder: discovered in soil bacterium)
• Allosteric: Inhibition type (Placeholder: partial, complex-selective)
• Immunosuppressant: Clinical use (Placeholder: originally approved for transplant)

Ternary complex formation

Placeholder: rapamycin-FKBP12 docks onto the FRB domain of mTOR.

mTORC1 vs mTORC2 selectivity

Placeholder: rapamycin preferentially inhibits mTORC1 acutely.

Dose and intermittent dosing strategies

Placeholder: intermittent low-dose regimens aim to limit side effects.

Placeholder key insight: partial, intermittent inhibition may separate longevity benefit from side effects.

Lifespan Extension Across Yeast, Worms, Flies, and Mice

Placeholder: rapamycin extends lifespan in every model organism tested so far.

• ~20-60%: C. elegans extension (Placeholder: worm lifespan studies)
• ~10-25%: Mouse extension (Placeholder: NIA Interventions Testing Program)
• 2004: ITP start year (Placeholder: multi-site mouse aging program)
• Yes: Sex difference (Placeholder: effect size differs by sex)

Yeast and invertebrate studies

Placeholder: earliest lifespan extension evidence came from yeast and worms.

The NIA Interventions Testing Program in mice

Placeholder: multi-cohort mouse studies replicated lifespan extension.

Dose-response and late-life initiation

Placeholder: benefits appear even when treatment starts late in life.

Placeholder key insight: late-onset dosing still extends mouse lifespan meaningfully.

Cellular Maintenance Pathways Activated by mTOR Inhibition

Placeholder: inhibiting mTOR unlocks autophagy and other repair pathways.

• Increased: Autophagy induction (Placeholder: ULK1 complex de-repressed)
• Improved: Proteostasis (Placeholder: reduced misfolded protein burden)
• Enhanced: Mitochondrial quality (Placeholder: mitophagy upregulation)
• Broad: Stress resistance (Placeholder: cross-stressor resilience)

Autophagy and proteostasis activation

Placeholder: autophagy clears damaged cellular components.

Mitochondrial and metabolic effects

Placeholder: mitochondrial turnover and metabolism shift favorably.

Hallmarks of aging addressed

Placeholder: mTOR inhibition touches multiple aging hallmarks at once.

Placeholder key insight: one pathway intersects several hallmarks of aging simultaneously.

From Mice to Humans — Open Questions and Clinical Trials

Placeholder: translating rodent longevity findings to humans remains unproven.

• Few: Human RCTs (aging) (Placeholder: limited long-term human trials)
• Improved: Immune biomarkers (Placeholder: PEARL trial vaccine response)
• Metabolic: Side-effect concerns (Placeholder: glucose and lipid effects)
• Low-Moderate: Confidence level (Placeholder: extrapolation uncertainty)

Human clinical trial landscape

Placeholder: small trials test immune and biomarker endpoints, not lifespan.

Safety and off-target effect concerns

Placeholder: chronic use raises metabolic and immune safety questions.

What would be needed to prove human benefit

Placeholder: long-term randomized trials with aging biomarker endpoints are needed.

Placeholder key insight: human lifespan extension remains a hypothesis, not an established fact.